

Mainstay Medical to present at 3rd Annual MedTech & Digital Health Forum for Technology & Healthcare Innovation

Dublin – Ireland, 23 September 2015 – Mainstay Medical International plc (**Mainstay** or the **Company**, listed on Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE), a medical device company focused on bringing to market ReActiv8[®], an implantable neurostimulation system to treat disabling Chronic Low Back Pain (CLBP), today announces that Peter Crosby, Chief Executive Officer, is to present at the 3rd Annual MedTech & Digital Health Forum for Technology & Healthcare Innovation, to be held on 28 September 2015 in Basel, Switzerland.

Mr. Crosby will present on Monday 28 September 2015 at 11:00am CEST. The presentation will be made available on the Company's website shortly after the meeting at:

http://www.mainstay-medical.com/investors/results_and_presentations.

In addition, Mr. Crosby will also be attending and taking one-to-one meetings at the CF&B European Large & MidCap Event in Paris on 7-8 October.

If you would like to meet with Mr. Crosby or a representative from Mainstay at either of these events, please contact the event organizers or investor-relations@mainstay-medical.com

- End -

About Mainstay

Mainstay is a medical device company which is developing an innovative implantable neurostimulation system, ReActiv8[®], for people with disabling Chronic Low Back Pain (CLBP). The Company is headquartered in Dublin, Ireland. It has subsidiaries operating in Ireland, the United States and Australia, and is listed on Euronext Paris (MSTY.PA) and the ESM of the Irish Stock Exchange (MSTY.IE).

About Chronic Low Back Pain

One of the recognised root causes of CLBP is impaired control by the nervous system of the muscles that dynamically stabilise the spine in the lower back, and an unstable spine can lead to back pain. ReActiv8 is designed to electrically stimulate the nerves responsible for contracting these muscles and thereby help to restore muscle control and improve dynamic spine stability, allowing the body to recover from CLBP.

People with CLBP usually have a greatly reduced quality of life and score significantly higher on scales for pain, disability, depression, anxiety and sleep disorders. Their pain and disability can persist despite the best available medical treatments, and only a small percentage of cases result from an identified pathological condition or anatomical defect that may be correctable with spine surgery. Their ability to work or be productive is seriously affected by the condition and the resulting days lost from work, disability benefits and health resource utilisation put a significant burden on individuals, families, communities, industry, and governments.

Further information can be found at www.mainstay-medical.com

ReActiv8 is an investigational device and is not approved for commercialisation anywhere in the world. CAUTION – in the United States, ReActiv8 is limited by federal law to investigational use only.

PR and IR Enquiries:

Consilium Strategic Communications (international strategic communications – business and trade media)

Chris Gardner, Mary-Jane Elliott, Matthew Neal, Hendrik Thys

Tel: +44 203 709 5700 / +44 7921 697 654

Email: mainstaymedical@consilium-comms.com

FTI Consulting (for Ireland)

Jonathan Neilan

Tel: +353 1 663 3686

Email: jonathan.neilan@fticonsulting.com

FTI Consulting (for France)

Astrid Villette

Tel: +33 1 47 03 69 51

Email: Astrid.Villette@fticonsulting.com

Investor Relations:

The Trout Group LLC

Jillian Connell

Tel: +1 646 378 2956 / +1 617 309 8349

Email: jconnell@troutgroup.com

ESM Advisers:

Fergal Meegan or Barry Murphy, Davy

Tel: +353 1 679 6363

Email: fergal.meegan@davy.ie or barry.murphy2@davy.ie